MoonLake Immunotherapeutics has launched Phase 3 of the IZAR program for the Nanobody® sonelokimab in individuals suffering from active psoriatic arthritis.

Mipomersen, developed by Isis Pharmaceuticals and marketed by Genzyme, is an antisense oligonucleotide that targets the apolipoprotein B-100 (ApoB-100) mRNA.

Gan & Lee Pharmaceuticals reported favorable Phase 1 outcomes for its oral GLP-1 receptor agonist, GZR18 tablet, in healthy subjects, showing a weight loss of 4.16% over two weeks.

Omaveloxolone is a small molecule drug developed by Reata Pharmaceuticals, Inc. that targets the Nrf2 protein.

Pimicotinib meaningfully enhanced results for patients with tenosynovial giant cell tumor in an international Phase III study.

Brentuximab Vedotin, also known as Adcetris, is an antibody-drug conjugate (ADC) developed by Seattle Genetics and Takeda Pharmaceutical Company.

New BLA for Datopotamab Deruxtecan filed in the U.S. for fast-track approval in patients with advanced EGFR-mutated non-small cell lung cancer who have received prior treatment.

Palbociclib was first approved in the United States in February 2015 and has since been approved in other countries around the world.

Apollo Therapeutics has secured an exclusive license from Sunshine Lake Pharma for a clinical-stage dual receptor agonist targeting FGF21 and GLP-1.

Imetelstat is a first-in-class telomerase inhibitor developed by Geron Corporation, targeting the enzyme telomerase.

KOSELUGO® (Selumetinib) Shows Significant Improvement in Response Rate Compared to Placebo in Adults with Symptomatic Neurofibromatosis Type 1.

PF-07328948 is a small molecule drug developed by Pfizer Inc. The drug targets BCKDK and falls within the therapeutic area of cardiovascular diseases.